Furthermore, studies showed that C5 antibodies are a promising new treatment option for patients with other neurological diseases, such as pneumococcal meningitis, neuromyelitis optica, and myasthenia gravis [31, 35, 36]. The gene discussed is C5; the disease is neuromyelitis optica.